Juliette Madrigal Dersch
Internal Medicine · Meadowlakes, TXNPI 1710103668
Payments from drug & device makers
Across 144 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$359
- GSK$353
- AbbVie$340
- Otsuka America Pharmaceutical, Inc.$216
- AstraZeneca$209
- Novo Nordisk$126
- plus $773 from 16 others
What the payments were for
- Food & beverage$2,376100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $359 |
| GSK | 21 | $353 |
| AbbVie(2 entities) | 22 | $340 |
| Otsuka America Pharmaceutical, Inc. | 12 | $216 |
| AstraZeneca | 14 | $209 |
| Novo Nordisk | 9 | $126 |
| Amgen | 7 | $90 |
| IBSA Pharma Inc. | 6 | $88 |
| Boehringer Ingelheim | 4 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Abbott | 3 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 3 | $51 |
| Genentech USA, Inc. | 3 | $48 |
| Bayer | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Cranial Technologies, Inc | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Corcept Therapeutics | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
How this compares
$2,376 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 51 | $53,811 |
| FarxigaDapagliflozin Propanediol | 59 | $48,984 |
| JanuviaSitagliptin Phosphate | 28 | $27,596 |
| EliquisApixaban | 15 | $12,825 |
| TrintellixVortioxetine Hydrobromide | 19 | $10,299 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $9,435 |
| Memantine Hcl ErMemantine Hcl | 14 | $4,183 |
| Rosuvastatin Calcium | 225 | $2,237 |
| Levothyroxine Sodium | 173 | $2,113 |
| SynthroidLevothyroxine Sodium | 13 | $1,348 |
| Estradiol | 32 | $1,253 |
| Olmesartan Medoxomil | 68 | $1,191 |
| Duloxetine Hcl | 60 | $1,148 |
| Tamsulosin Hcl | 61 | $884 |
| Eszopiclone | 36 | $879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $359 | $53,81151 claims |
| AstraZenecaFarxiga | $209 | $48,98459 claims |
| AbbVieSynthroid | $340 | $1,34813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Meadowlakes
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.